following are the game changing steps for NNLX beg
Post# of 9122
(Total Views: 457)
Posted On: 06/21/2018 12:14:04 PM
following are the game changing steps for NNLX beginning july 12 2017-- LESS THAN 1 YEAR AGO
Parties interested in licensing etc flat pack patent could not make a serious offer til publication ca april 11,which signaled the end of a 9 month period for companies to oppose the patent in europe
big companies take dd and manipulation seriously-negotiating w them,unless you want to be taken over and destroyed via bad agreement, is difficult,and in a biotech you have 3 groups of people all speaking different languages-scientists businessmen and lawyers, w offers etc going through the chain of command ,including board approvals on both ends.How fast do u you think this happens???? Usually a slow process.
Have you seen long and complicated contracts which have to be negotiated?
Once it took me 7 years just to negotiate a land transaction due to interference by outside parties and unbridled greed.
Lawyers are not trained to do what is right and fair-just the opposite- in school we are taught," forget childhood concepts of truth justice integrity honor morality -those things no longer exist.There is no truth justice etc.You are hitmen." Thats the nonmorality.
once i was instrumental in getting landmark state legislation passed despite the trainloads of manipulators and lawyers on the other side,which then took the issue federal-federal pre-emption,again due to unbridled greed.
These are people trained to be evil and almost no one who is good and still has a conscience is even accepted into the fraternity.
These are the battles little old NNLX has to confront with the big players. Yes NNLX could accept whatever they offer and quickly be destroyed.
Have you ever had to sign bank etc agreements whereby at the end of the process you felt like just kicking them where it hurts as they demand your soul and your unborn children.It takes a lot of patience and work to do what NNLX is trying to do.
Posted On: 04/12/2018 12:44:04 PM
Posted By: Kachingpdx1
Further European Patent Office Information on FlatPack Patent for Sale and Licensing
International Patent Offering
NanoLogix is pleased to announce receipt today (dated 11 April 2018) of notice from the European Patent Office (EPO) of the expiration of the nine-month opposition filing period for the FlatPack petri plate extended-life packaging patent (European Patent No. 2699491). The reason for this update from Nanologix is to inform all interested parties that out of the fourteen signatory countries chosen and paid for the registration and validation of the Flatpack Patent in early September 2017, prior to the receipt of this notice from the EPO, of the signatory states for the EU Patent treaty only the three non-EU member states of Sweden, Croatia, and Turkey had published notice of validation of the Flatpack patent in their respective patent bulletins.
Notice from the EPO states: "The entry in the Register of European Patents will be automatically generated by the electronic data processing system".
Further information from this notice: "This European patent has become wholly equivalent to a bundle of national patents in the designated states in which the patent was validated".
?The publication in the EU Patent Registry is the essential and final step to enable NanoLogix to offer a fully registered and validated patent in the EU for license and/or sale. This step is in accordance with the Company's stated goal of using receipts from those efforts to fund expansion of agar-filled petri plate production in the US and complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
?The Company is currently seeking to raise $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:
?Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.
?Pending: Brazil, Canada
Posted On: 04/09/2018 11:28:36 AM
Posted By: Kachingpdx1
[4-9-18] Update on Patents Offered for Sale and Licensing, Grant Applications
International Patent Offering
NanoLogix is pleased to provide this update on the ongoing work on the sale and/or licensing of the international issued FlatPack patents, and filed and in-process applications to the National Institutes of Health, The National Science Foundation and BARDA
We have had interest in the technology from companies in France, Spain, Turkey, Serbia, South Africa, and China. The interest varies from licensing arrangements, purchase, and through direct representation of our products.
The Company is currently in the process of raising $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:
Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.
Pending: Brazil, Canada
Grant Applications
One grant application has been filed with the National Institutes of Health (NIH) and two additional are planned with The National Science Foundation (NSF) and the Biomedical Advance Research and Development Authority (BARDA). Two of the applications are for funding for a pre-test for use with the N-Assay modified ELISA diagnostic and the BARDA application is for the use of the N-Assay for diagnostics of bio-threat agents.
As stated with the previous update from November, while there is strong competition for the grants, we believe the N-Assay and what it offers will be attractive to the grant evaluators.
[11-27-17] Update on Patents Offered for Sale, UTI Presentation at CAOG, and NSF Grant Application-see post 4050 11-27-17
International Patent Offering
NanoLogix is pleased to provide this update on the ongoing work on the sale of the European and China issued FlatPack patents, the poster presentation dealing with the seriousness of the threat from Urinary Tract Infections (UTI) with the need for new rapid methods for diagnostics for UTI infections, and an in-process application to the National Science Foundation for a $1.5 million grant.
Since our first announcement of the offer of 12 July we have registered the patent in fourteen EU Patent Agreement signatory countries. That registration was completed by 7 September. At that time the official status of the FlatPack patent in Europe was recognized in those fourteen countries. Since 7 September, two of those countries, Sweden and Croatia, out of the fourteen countries in which the patent has been registered, have published that information in either their own national patent bulletins or the EU Patent bulletin. This publication step is generally required in order for a formal acceptance of the patent validity by interested parties. NanoLogix has no control over the timing of individual Country publication and hopes the remainder of the bulletin notifications could be completed by the end of the current quarter, fully realizing each country involved possesses its own separate bureaucracy and timetables. That stated, we are pleased to have had interest in the technology from companies in three European and adjacent countries.
For the offering of the FlatPack patent in China we are using the services of a broker in Asia and have as yet to receive notice of significant interest. China and Intellectual property rights have an interesting and varied history so we hope to find a large entity in China with the vision to recognize, acquire, and protect the granted China patent rights.
Central Association of Obstetricians and Gynecologists
Dr. Jonathan Faro, PhD, MD presented the following poster at the CAOG Annual Meeting in Scottsdale, Arizona:
179462903_NNLX-POSTER.jpg
NanoLogix and the authors are in agreement on the need for a rapid definitive diagnostic for UTI and the N-Assay and its soon to be developed screening pre-test are the needed tools to fill the projected need.
National Science Foundation Grant Application
NanoLogix, the Houston medical personnel involved in the N-Assay development and a professional grant writer are finalizing a grant application for $1,500,000.00 from the NSF for funding of both development of a screening ‘pre-test” to be used in conjunction with the N-Assay and also finalization for marketing of the N-Assay. Link to what is offered by the NSF can be found here:
NSF SBIR | NSF SBIR
While there is strong competition for the grants, we believe the N-Assay and what it offers will be attractive to the grant evaluators.
NanoLogix Offers EU, Hong Kong & PRC Petri FlatPack Packaging Patents For $35 - $50 Million
12:08 pm ET July 12, 2017 (Globe Newswire) Print
NanoLogix (OTC:NNLX) is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong (Patent EP269949), and the People's Republic of China (PRC Patent CN103842265 (
) for their unique and exclusively licensed petri plate packaging system known as the FlatPack.
The FlatPack, a method of vacuum-packing for petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
The FlatPack Patent has been granted in the USA, Mexico, New Zealand, South Africa, the EU (40 Patent signatory countries including Hong Kong), the People's Republic of China, and Chile, and is pending in South Korea, Brazil, and Canada.
The offering price range is cited as the estimate of value for the PRC patent ($35mm) and the EU patent ($15mm). Any interest in patent purchase for the other international granted patents is open for discussion.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPack petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for NanoLogix, basically an R&D company for most of its existence with FlatPack petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
Sales proceeds will be used for NanoLogix expansion of petri production and sales domestically and development and marketing of their N-Assay Rapid Bacteria Diagnostic Test. The N-Assay provides the most rapid and sensitive diagnostic for bacteria available, coupled with near-simultaneous determination of antibiotic sensitivity.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused on development and production of rapid diagnostics and petri plates. Its products offer accelerated detection and identification of microorganisms for diagnostics, and unrivaled shelf life and durability for petri plates. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted or licensed to NanoLogix can be used in the areas of applied microbiology, soil microbiology, microbial physiology, pharmacology, and antibiotic sensitivity.
For more information visit: http://www.nanologix.com
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
CONTACT INFORMATION
Contact
NanoLogix, Inc.
Carol Surrena
330-534-0800
Email Contact: Carol@nanologix.com
Parties interested in licensing etc flat pack patent could not make a serious offer til publication ca april 11,which signaled the end of a 9 month period for companies to oppose the patent in europe
big companies take dd and manipulation seriously-negotiating w them,unless you want to be taken over and destroyed via bad agreement, is difficult,and in a biotech you have 3 groups of people all speaking different languages-scientists businessmen and lawyers, w offers etc going through the chain of command ,including board approvals on both ends.How fast do u you think this happens???? Usually a slow process.
Have you seen long and complicated contracts which have to be negotiated?
Once it took me 7 years just to negotiate a land transaction due to interference by outside parties and unbridled greed.
Lawyers are not trained to do what is right and fair-just the opposite- in school we are taught," forget childhood concepts of truth justice integrity honor morality -those things no longer exist.There is no truth justice etc.You are hitmen." Thats the nonmorality.
once i was instrumental in getting landmark state legislation passed despite the trainloads of manipulators and lawyers on the other side,which then took the issue federal-federal pre-emption,again due to unbridled greed.
These are people trained to be evil and almost no one who is good and still has a conscience is even accepted into the fraternity.
These are the battles little old NNLX has to confront with the big players. Yes NNLX could accept whatever they offer and quickly be destroyed.
Have you ever had to sign bank etc agreements whereby at the end of the process you felt like just kicking them where it hurts as they demand your soul and your unborn children.It takes a lot of patience and work to do what NNLX is trying to do.
Posted On: 04/12/2018 12:44:04 PM
Posted By: Kachingpdx1
Further European Patent Office Information on FlatPack Patent for Sale and Licensing
International Patent Offering
NanoLogix is pleased to announce receipt today (dated 11 April 2018) of notice from the European Patent Office (EPO) of the expiration of the nine-month opposition filing period for the FlatPack petri plate extended-life packaging patent (European Patent No. 2699491). The reason for this update from Nanologix is to inform all interested parties that out of the fourteen signatory countries chosen and paid for the registration and validation of the Flatpack Patent in early September 2017, prior to the receipt of this notice from the EPO, of the signatory states for the EU Patent treaty only the three non-EU member states of Sweden, Croatia, and Turkey had published notice of validation of the Flatpack patent in their respective patent bulletins.
Notice from the EPO states: "The entry in the Register of European Patents will be automatically generated by the electronic data processing system".
Further information from this notice: "This European patent has become wholly equivalent to a bundle of national patents in the designated states in which the patent was validated".
?The publication in the EU Patent Registry is the essential and final step to enable NanoLogix to offer a fully registered and validated patent in the EU for license and/or sale. This step is in accordance with the Company's stated goal of using receipts from those efforts to fund expansion of agar-filled petri plate production in the US and complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
?The Company is currently seeking to raise $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:
?Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.
?Pending: Brazil, Canada
Posted On: 04/09/2018 11:28:36 AM
Posted By: Kachingpdx1
[4-9-18] Update on Patents Offered for Sale and Licensing, Grant Applications
International Patent Offering
NanoLogix is pleased to provide this update on the ongoing work on the sale and/or licensing of the international issued FlatPack patents, and filed and in-process applications to the National Institutes of Health, The National Science Foundation and BARDA
We have had interest in the technology from companies in France, Spain, Turkey, Serbia, South Africa, and China. The interest varies from licensing arrangements, purchase, and through direct representation of our products.
The Company is currently in the process of raising $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:
Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.
Pending: Brazil, Canada
Grant Applications
One grant application has been filed with the National Institutes of Health (NIH) and two additional are planned with The National Science Foundation (NSF) and the Biomedical Advance Research and Development Authority (BARDA). Two of the applications are for funding for a pre-test for use with the N-Assay modified ELISA diagnostic and the BARDA application is for the use of the N-Assay for diagnostics of bio-threat agents.
As stated with the previous update from November, while there is strong competition for the grants, we believe the N-Assay and what it offers will be attractive to the grant evaluators.
[11-27-17] Update on Patents Offered for Sale, UTI Presentation at CAOG, and NSF Grant Application-see post 4050 11-27-17
International Patent Offering
NanoLogix is pleased to provide this update on the ongoing work on the sale of the European and China issued FlatPack patents, the poster presentation dealing with the seriousness of the threat from Urinary Tract Infections (UTI) with the need for new rapid methods for diagnostics for UTI infections, and an in-process application to the National Science Foundation for a $1.5 million grant.
Since our first announcement of the offer of 12 July we have registered the patent in fourteen EU Patent Agreement signatory countries. That registration was completed by 7 September. At that time the official status of the FlatPack patent in Europe was recognized in those fourteen countries. Since 7 September, two of those countries, Sweden and Croatia, out of the fourteen countries in which the patent has been registered, have published that information in either their own national patent bulletins or the EU Patent bulletin. This publication step is generally required in order for a formal acceptance of the patent validity by interested parties. NanoLogix has no control over the timing of individual Country publication and hopes the remainder of the bulletin notifications could be completed by the end of the current quarter, fully realizing each country involved possesses its own separate bureaucracy and timetables. That stated, we are pleased to have had interest in the technology from companies in three European and adjacent countries.
For the offering of the FlatPack patent in China we are using the services of a broker in Asia and have as yet to receive notice of significant interest. China and Intellectual property rights have an interesting and varied history so we hope to find a large entity in China with the vision to recognize, acquire, and protect the granted China patent rights.
Central Association of Obstetricians and Gynecologists
Dr. Jonathan Faro, PhD, MD presented the following poster at the CAOG Annual Meeting in Scottsdale, Arizona:
179462903_NNLX-POSTER.jpg
NanoLogix and the authors are in agreement on the need for a rapid definitive diagnostic for UTI and the N-Assay and its soon to be developed screening pre-test are the needed tools to fill the projected need.
National Science Foundation Grant Application
NanoLogix, the Houston medical personnel involved in the N-Assay development and a professional grant writer are finalizing a grant application for $1,500,000.00 from the NSF for funding of both development of a screening ‘pre-test” to be used in conjunction with the N-Assay and also finalization for marketing of the N-Assay. Link to what is offered by the NSF can be found here:
NSF SBIR | NSF SBIR
While there is strong competition for the grants, we believe the N-Assay and what it offers will be attractive to the grant evaluators.
NanoLogix Offers EU, Hong Kong & PRC Petri FlatPack Packaging Patents For $35 - $50 Million
12:08 pm ET July 12, 2017 (Globe Newswire) Print
NanoLogix (OTC:NNLX) is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong (Patent EP269949), and the People's Republic of China (PRC Patent CN103842265 (
) for their unique and exclusively licensed petri plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing for petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
The FlatPack Patent has been granted in the USA, Mexico, New Zealand, South Africa, the EU (40 Patent signatory countries including Hong Kong), the People's Republic of China, and Chile, and is pending in South Korea, Brazil, and Canada.
The offering price range is cited as the estimate of value for the PRC patent ($35mm) and the EU patent ($15mm). Any interest in patent purchase for the other international granted patents is open for discussion.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPack petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for NanoLogix, basically an R&D company for most of its existence with FlatPack petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
Sales proceeds will be used for NanoLogix expansion of petri production and sales domestically and development and marketing of their N-Assay Rapid Bacteria Diagnostic Test. The N-Assay provides the most rapid and sensitive diagnostic for bacteria available, coupled with near-simultaneous determination of antibiotic sensitivity.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused on development and production of rapid diagnostics and petri plates. Its products offer accelerated detection and identification of microorganisms for diagnostics, and unrivaled shelf life and durability for petri plates. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted or licensed to NanoLogix can be used in the areas of applied microbiology, soil microbiology, microbial physiology, pharmacology, and antibiotic sensitivity.
For more information visit: http://www.nanologix.com
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
CONTACT INFORMATION
Contact
NanoLogix, Inc.
Carol Surrena
330-534-0800
Email Contact: Carol@nanologix.com
(3)
(0)Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼